EDIT 8-K 2026-11-09
Editas Medicine, Inc. (EDIT) 8-K dated 2026-11-09 — accession 0001650664-26-000100.
Editas Medicine, Inc. (EDIT) is a biotechnology company listed on NASDAQ.
EDIT: Editas Medicine Annou nces Third Quarter 2026 Results and Bu siness Upd…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported EDIT revenue for 2025-12-31 was $40.5M. Net income was -$160.1M. Revenue was up 25.4% from 2024-12-31 to 2025-12-31. EDIT currently screens at market cap $375.2M.
Not investment advice. The EDIT SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects to complete enrollment in Part 1 of the Strive study, with topline safety and efficacy results from Part 1 available in
Why it matters
- expects to complete enrollment in Part 1 of the Strive study, with topline safety and efficacy results from Part 1 available in
- We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine f…